Table 3.

Estimated interactions for each treatment class and potential effect modifier, and estimated individual level treatment effects†

	Results for the following treatment classes:
	Anti‐TNFα	IL‐17A blocker
Effect modifier interaction
Previous systemic use	−0.00 (−0.38, 0.35)	0.12 (−0.21, 0.46)
Duration of psoriasis, per 10 years	0.14 (−0.03, 0.30)	0.17 (0.02, 0.33)
Body surface area, per 10%	0.06 (−0.05, 0.17)	0.02 (−0.09, 0.13)
Weight, per 10 kg	−0.10 (−0.18, −0.02)	−0.04 (−0.11, 0.04)
Psoriatic arthritis	0.01 (−0.43, 0.48)	0.25 (−0.17, 0.71)
Reference individual treatment effect
IXE Q2W		2.82 (2.56, 3.10)
IXE Q4W		2.52 (2.25, 2.80)
ETN	1.67 (1.38, 1.96)
SEC 150		2.16 (1.86, 2.49)
SEC 300		2.47 (2.17, 2.79)

†All estimates are standardized mean differences versus placebo, with 95% credible intervals.